{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:47:31Z","timestamp":1781916451702,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.lungcan.2022.11.004","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T12:57:29Z","timestamp":1667825849000},"page":"146-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer"],"prefix":"10.1016","volume":"174","author":[{"given":"Julien","family":"Mazieres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Iadeluca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice T.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"de Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Reisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Thurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Polli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2022.11.004_b0005","first-page":"1023","article-title":"Quality of life of patients with lung cancer","volume":"9","author":"Polanski","year":"2016","journal-title":"Onco Targets Ther."},{"issue":"1","key":"10.1016\/j.lungcan.2022.11.004_b0010","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12955-017-0735-4","article-title":"Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: Results from a prospective medical record registry study","volume":"15","author":"Walker","year":"2017","journal-title":"Health Quality Life Outcomes."},{"issue":"4","key":"10.1016\/j.lungcan.2022.11.004_b0015","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3111\/13696998.2014.1003644","article-title":"Brain metastases in patients with ALK+ non-small cell lung cancer: Clinical symptoms, treatment patterns and economic burden","volume":"18","author":"Gu\u00e9rin","year":"2015","journal-title":"J. Med. Econ."},{"issue":"2","key":"10.1016\/j.lungcan.2022.11.004_b0020","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3390\/ijms22020593","article-title":"Treatment of brain metastases of non-small cell lung carcinoma","volume":"22","author":"Rybarczyk-Kasiuchnicz","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.lungcan.2022.11.004_b0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cllc.2017.10.003","article-title":"Effect of brain metastasis on patient-reported outcomes in advanced NSCLC treated in real-world community oncology settings","volume":"19","author":"Walker","year":"2018","journal-title":"Clin. Lung Cancer."},{"issue":"17","key":"10.1016\/j.lungcan.2022.11.004_b0030","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","article-title":"Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases","volume":"33","author":"Costa","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2022.11.004_b0035","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2022.11.004_b0040","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"ALEX trial investigators, Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl. J. Med."},{"issue":"22","key":"10.1016\/j.lungcan.2022.11.004_b0045","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","article-title":"Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer","volume":"36","author":"Solomon","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2022.11.004_b0050","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.lungcan.2022.11.004_b0055","doi-asserted-by":"crossref","unstructured":"G. Selvaggi, H.A. Wakelee, T. Mok, Y.-L. Wu, M. Reck, A. Chiappori, I. Cicin, D.H. Lee, V. Breder, Y. Fan, S. Orlov, E. Poddubskaya, Z. Wang, Y. Cheng, Y. Liu, G. Wu, L. Mao, J. Zhou, V. Oertel, L. Horn, C. Liang, Phase III randomized study of ensartinib vs crizotinib in anaplastic lymphoma kinase (ALK) positive NSCLC patients: eXalt3, J. Thorac. Oncol. 15 (10) (2020) e41-e42. Abstract ID:1882. https:\/\/doi.org\/10.1016\/j.jtho.2020.08.003.","DOI":"10.1016\/j.jtho.2020.08.003"},{"issue":"7","key":"10.1016\/j.lungcan.2022.11.004_b0060","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study","volume":"14","author":"Camidge","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"31","key":"10.1016\/j.lungcan.2022.11.004_b0065","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.20.00505","article-title":"Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: Second interim analysis of the phase III ALTA-1L trial","volume":"38","author":"Camidge","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2022.11.004_b0070","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"Johnson","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lungcan.2022.11.004_b0075","article-title":"LORBRENA\u00ae (lorlatinib)","author":"Pfizer Inc","year":"2021","journal-title":"Prescribing information,"},{"issue":"21","key":"10.1016\/j.lungcan.2022.11.004_b0080","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl. J. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2022.11.004_b0085","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: Results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2022.11.004_b0090","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: An international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2022.11.004_b0095","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jtho.2020.12.022","article-title":"Lorlatinib should not be considered as the preferred first-line option in patients with advanced ALK rearranged NSCLC","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2022.11.004_b0100","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jtho.2020.12.021","article-title":"Lorlatinib should be considered as the preferred first-line option in patients with advanced ALK-rearranged NSCLC","volume":"16","author":"Nagasaka","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2022.11.004_b0105","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","article-title":"Clinical management of adverse events associated with lorlatinib","volume":"24","author":"Bauer","year":"2019","journal-title":"Oncologist."},{"key":"10.1016\/j.lungcan.2022.11.004_b0110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.lungcan.2020.02.011","article-title":"Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer","volume":"144","author":"Peters","year":"2020","journal-title":"Lung Cancer."},{"issue":"5","key":"10.1016\/j.lungcan.2022.11.004_b0115","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.lungcan.2022.11.004_b0120","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","article-title":"EORTC Study Group on Quality of Life, The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials","volume":"30","author":"Bergman","year":"1994","journal-title":"Eur. J. Cancer."},{"issue":"10","key":"10.1016\/j.lungcan.2022.11.004_b0125","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.lungcan.2022.11.004_b0130","article-title":"EORTC Quality of Life Group, EORTC quality of life group translation procedure","author":"Kuli\u015b","year":"2017","journal-title":"Fourth Edition."},{"issue":"24","key":"10.1016\/j.lungcan.2022.11.004_b0135","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.2217\/fon-2019-0185","article-title":"Patient-reported outcomes and quality of life in advanced ALK+ non-small-cell lung cancer trial of brigatinib (ALTA)","volume":"15","author":"Lenderking","year":"2019","journal-title":"Future Oncol. (London, England)."},{"issue":"5","key":"10.1016\/j.lungcan.2022.11.004_b0140","doi-asserted-by":"crossref","first-page":"e000364","DOI":"10.1136\/esmoopen-2018-000364","article-title":"Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer","volume":"3","author":"Ou","year":"2018","journal-title":"ESMO Open."},{"key":"10.1016\/j.lungcan.2022.11.004_b0145","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.lungcan.2019.10.002","article-title":"Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer","volume":"138","author":"P\u00e9rol","year":"2019","journal-title":"Lung Cancer."},{"issue":"Suppl 4","key":"10.1016\/j.lungcan.2022.11.004_b0150","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/S0959-8049(01)00448-8","article-title":"EORTC Quality of Life Group, Quality of Life Unit, Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer","volume":"38","author":"Fayers","year":"2002","journal-title":"Eur. J. Cancer."},{"issue":"1","key":"10.1016\/j.lungcan.2022.11.004_b0155","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.11.004_b0160","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fonc.2018.00088","article-title":"Brain metastases in oncogene-addicted non-small cell lung cancer patients: Incidence and treatment","volume":"8","author":"Remon","year":"2018","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2022.11.004_b0165","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF00439229","article-title":"The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30","volume":"5","author":"King","year":"1996","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.lungcan.2022.11.004_b0170","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.lungcan.2021.03.005","article-title":"Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L)","volume":"155","author":"Garcia Campelo","year":"2021","journal-title":"Lung Cancer."},{"issue":"1","key":"10.1016\/j.lungcan.2022.11.004_b0175","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1186\/s12885-021-08977-0","article-title":"Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: A meta-analysis of clinical trials","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Cancer."},{"issue":"1","key":"10.1016\/j.lungcan.2022.11.004_b0180","first-page":"CD013453","article-title":"Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer","volume":"1","author":"Cameron","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"issue":"28","key":"10.1016\/j.lungcan.2022.11.004_b0185","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1200\/JCO.22.00824","article-title":"Therapy for stage IV non\u2013small-cell lung cancer with driver alterations: ASCO living guideline","volume":"40","author":"Singh","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 4","key":"10.1016\/j.lungcan.2022.11.004_b0190","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222006778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222006778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:03:18Z","timestamp":1759237398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222006778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":38,"alternative-id":["S0169500222006778"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.11.004","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}